KemPharm Inc

KMPH

$8.00

+32.5% last 12 months

Market Cap

$288 Million

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$5.81 - $18.15

The lowest and highst price in the last 52 weeks.

Price-Earnings Ratio

0.0x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Market Cap $288 Million
Enterprise Value -
Dividend Yield $0.00 (0.0%)
1 Year Return +32.5%
52-Week High $18.15
52-Week Low $5.81
Beta 1.3
Outstanding Shares 35.3 Million
Avg 30 Day Volume 430 Thousand

Valuation

P/E Ratio 0.0
PEG -
Earnings per Share $0.00
Price to Sales Ratio -
Price to Book Ratio -
Revenue to Enterprise Value -
EBIT to Enterprise Value -
Total Debt to Enterprise Value -
Debt to Equity -

Profitability

Revenue -
Gross Profit -
EBIT -
Net Income -
Profit Margin -
Quarterly Earnings Growth (YoY) -
Return on Equity -
Return on Assets -
Return on Invested Capital -

Insider trades

11,725 shares bought (4 transactions)

No sells

1,380 shares bought (3 transactions)

No sells

510 shares bought (1 transactions)

No sells

No purchases

No sells

Q2 2021 Q3 2021 Q4 2021 Q1 2022

About KemPharm Inc

CEO: Travis Mickle

Employees: 22

Industry: Pharmaceutical Preparation Manufacturing

KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes its proprietary LAT™ technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm's prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder. KemPharm's co-lead clinical development candidates for the treatment of ADHD, KP415 and KP484, are both based on a prodrug of d-methylphenidate, but have differing duration/effect profiles. In addition, KemPharm has received FDA approval for APADAZ®, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.

Similar stocks

Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc
Agile Therapeutics Inc
Agile Therapeutics Inc
Theravance Biopharma Inc
Theravance Biopharma Inc
ANI Pharmaceuticals Inc
ANI Pharmaceuticals Inc

News